Navigation Links
Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
Date:5/6/2013

Minneapolis, MN, May 6, 2013 For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. Aggressive warfarin anticoagulation is accompanied by significant annual risk of bleeding, while inadequate anticoagulation of a mechanical artificial valve has been associated with high risk of clotting problems that can cause strokes.

A newer generation mechanical heart valve, manufactured by On-X Life Technologies, Austin, TX, has several design features that make it more efficient and less likely to clot. The FDA is allowing a randomized trial to be conducted to determine whether it is safe and effective to treat patients with an On-X mechanical aortic valve with less aggressive anticoagulation than has previously been recommended by the American Heart Association and American College of Cardiology.

In an interim report to be presented at the 93rd AATS Annual Meeting in Minneapolis on May 6, 2013, John D. Puskas, MD, Professor and Associate Chief of the Division of Cardiothoracic Surgery, Emory University School of Medicine, Athens, GA, and his co-investigators show that lower dose anticoagulation therapy, combined with low-dose aspirin, resulted in a reduction of 55 to 60% of the incidence of adverse bleeding events without significant increases in stroke, transient ischemic attack or total neurological events when used in conjunction with the On-X mechanical aortic valve.

As part of the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), a control group of patients received standard treatment of warfarin administered to maintain a target range of the International Normalized Ratio (INR) of 2.0-3.0. The second treatment group received low-dose warfarin, targeting a
'/>"/>

Contact: Nicole Baritot
press@aats.org
978-299-4520
American Association for Thoracic Surgery
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Low-Dose Pill Linked to Pain During Orgasm, Study Finds
2. Resistance to low-dose aspirin therapy extremely rare
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. Low-dose CT screening may benefit individuals at increased risk for lung cancer
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. CWRU School of Medicine researchers discover new target for personalized cancer therapy
7. Women's Excellence in Menopause Now Offering Treatment Options for Decreased Sex Drive near Rochester Hills, Michigan; Natural Therapy Available via Bioidentical Hormones
8. TherapySites and the AAMFT are Offering an Educational Webinar, "4 Online Marketing Trends You Can't Afford To Ignore"
9. North American Seminars Introduces Vestibular Rehabilitation - Examination and Treatment, a New Physical Therapy Online Continuing Education Course
10. Clarifying the effect of stem cell therapy on cancer
11. Get Rid of Varicose Veins in Time for Summer with Shaft Medical San Diego’s Micro Needle Sclerotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The need ... In an effort to provide comfort to patients as well as visiting friends and ... solution: free phone charging stations. , The stations - powered by ChargeItSpot , ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, MD, FACS has ... Professor of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious ... university, developing a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
(Date:7/30/2015)... Wisconsin (PRWEB) , ... July 30, 2015 , ... Quintessa ... Kybella is a nonsurgical treatment designed specifically for the elimination of ... one of the first locations in the state of Wisconsin to offer this innovative ...
Breaking Medicine News(10 mins):Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2
... Experts agree that long-term alcohol abuse is detrimental to ... to a study published in Age and Ageing ... that light-to-moderate alcohol consumption may decrease the risk of ... studies have suggested the prevalence of alcohol-related dementia to ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... announcement Monday that researchers reconfigured immune cells so that they became ... But they say the jury is out on whether the ... is ultimately a cure or what,s called a "functional cure" -- ...
... The National Eye Institute (NEI) and Food and Drug ... functional vision-related endpoints for clinical trials of visual prostheses ... visual acuity, visual fields and contrast sensitivity. These assessments ... test outcomes. Today, functional vision outcomes ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- Half of ... new health care reform law that requires all Americans not ... support it, a new Harris Interactive/HealthDay poll finds. ... seem to sway opinion back toward support for it. ...
... March 1, 2011 The American Sociological Association (ASA) ... dedicated to research on the sociology of mental health ... Health (SMH) journal features original, peer-reviewed studies that ... the social origins of mental health and illness, the ...
... Ohio New research has identified a small subset of ... to a rare incurable form of leukemia. The study, ... Center Arthur G. James Cancer Hospital and Richard J. ... lymphocyte leukemia can occur in a small subset of white ...
Cached Medicine News:Health News:Research suggests alcohol consumption helps stave off dementia 2Health News:Research suggests alcohol consumption helps stave off dementia 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 4Health News:Visual prostheses: Symposium to explore combining functional endpoints 2Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 2Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 3Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 4Health News:ASA launches new journal focused on mental health and illness 2Health News:A small subset of normal white blood cells gives rise to a rare leukemia, study shows 2
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... University of Alabama at Birmingham (UAB) Health System became ... to utilize intrafraction motion review (IMR), or "triggered imaging," ... cancer.  IMR, which is a unique capability of the ... VAR ) enables visual verification that a tumor ...
... N.J., Nov. 21, 2011  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will ... Piper Jaffray Health Care Conference on Wednesday, November ... York Palace hotel. About Omthera ...
Cached Medicine Technology:Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 2Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 3
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: